Market Sell-Off Will Expose Biotech Buying Opportunities
Hardest hit are smaller biotechnology companies that aren't yet generating revenues. This, of course, includes some our past portfolio recommendations. We took profits on several of them late last and early this year. All three of these companies have seen their shares sell off sharply from recent peaks, along with much of the rest of the biotechnology market. Our March pick, for example, is still languishing below our buy price. The recent sell-off provides an opportunity to buy shares cheap.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.